Extended Data Fig. 7.

Cervical cancer mortality ASR % reductions assuming (A) HPV positive and triage negative women are followed-up after 2 years with 10% loss-to-follow-up (black triangle), followed-up after 2 years with 30% loss-to-follow-up (grey triangle), followed-up at both 1- and 2- years with 10% loss-to-follow-up for each visit (black crosses)) and (B) assuming women treated for pre-cancer treatment (not known to have CIN3 + ) are followed-up after 2 years assuming with 30% loss-to-follow-up (gray triangle), followed-up after 1 year with cotesting assuming 10% loss-to-follow-up (black triangle). The dots represent reductions assuming base case assumptions for test performance and the error bars represent the reductions when assuming the best (upper range) and worst (lower range) primary test performance assumptions as described in Supplementary Table 3. *All positive women treated after assessment of eligibility for ablative treatment. **Triage positive referred to colposcopy. ^^VIA triage positive women treated after assessment of eligibility for ablative treatment. ^HPV16/18 positive women treated after assessment of eligibility for ablative treatment; women positive for HPV types other than HPV 16/18 (‘OHR’) are triaged with VIA.